Allogene Therapeutics (ALLO) Cash & Equivalents: 2019-2025
Historic Cash & Equivalents for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $37.8 million.
- Allogene Therapeutics' Cash & Equivalents fell 26.20% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year decrease of 26.20%. This contributed to the annual value of $75.2 million for FY2024, which is 9.54% down from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Cash & Equivalents is $37.8 million, which was down 27.74% from $52.3 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Cash & Equivalents high stood at $236.9 million for Q1 2021, and its period low was $37.8 million during Q3 2025.
- Over the past 3 years, Allogene Therapeutics' median Cash & Equivalents value was $69.2 million (recorded in 2023), while the average stood at $81.6 million.
- In the last 5 years, Allogene Therapeutics' Cash & Equivalents skyrocketed by 74.30% in 2021 and then tumbled by 69.34% in 2025.
- Allogene Therapeutics' Cash & Equivalents (Quarterly) stood at $173.3 million in 2021, then slumped by 64.28% to $61.9 million in 2022, then surged by 34.33% to $83.2 million in 2023, then dropped by 9.54% to $75.2 million in 2024, then fell by 26.20% to $37.8 million in 2025.
- Its Cash & Equivalents was $37.8 million in Q3 2025, compared to $52.3 million in Q2 2025 and $42.5 million in Q1 2025.